HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

9th Edition of International Conference on Dentistry
and Oral Health

September 02-04, 2024 | Madrid, Spain

September 02-04, 2024 | Madrid, Spain
ICDO 2019

Randa Essam Shaker

Randa Essam Shaker, Speaker at Dental Conferences
King Faisal Specialist Hospital and Research Center - Jeddah, Saudi Arabia
Title: Medication-Related osteonecrosis of the jaw; How much do we know?


Bisphosphonate (BF) is a class of drugs that prevents bone resorption and remodeling, and have been efficiently and safely used to treat osteoporosis, hypercalcemia of malignancy, bone metastasis of solid malignant rumors, Peget’s disease of the bone.
However the use of (BF) was found to cause side effects of which BRONJ as the most adverse effect. 
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) can be described as an area of exposed necrotic bone in the mouth more than 8 weeks either affecting the maxilla or the mandible in a person taking any BF and had not had radiation therapy in the craniofacial region.
BRONJ rarely reported prior to 2001. In September 2004, Novartis: manufacturer of intravenous BF  pamisronate (Aredia) and zoledronic  acid (Zometa), notified healthcare professionals of additions of the labeling of these products which provides cautionary language related to the development of osteonecrosis of the jaw (ONJ). In 2005: the FDA issued warning for the entire drug class (including oral BF).
Treatment recommendations exist, but a standard therapy has not yet been established for BRONJ.
Ruggiero et al, in 2006 proposed guidelines for the diagnosis, staging and management of BRONJ. Later Ruggiero at al and the American Association of Oral and  Maxillofacial Surgery (AAOMS) reported their position paper on BRONJ with an update of the previous classification (2014).

This lecture will cover:
-Their clinical applications 
-drug chemistry and actions
-Side effects of BF 
-Staging of BRONJ
-Treatment of BRONJ
-Latest management and recommendations


Dr. Randa Shaker
Consultant – Advanced General Dentistry
Department of Dentistry
King Faisal Specialist Hospital and Research Center- Jeddah
Present Position:
  Consultant – Advanced General Dentistry and  Residency Program Director
Medical Degree:              Bachelor of dental surgery, KSU,1993
AEGD, Ohio state university, Columbus, Oh, 1996
Masters in dental Science , Ohio state Uni, Columbus, Ohio, 1997
Residency in hospital dentistry, McGill University, Montreal, Quebec. 1999
Fellowship in Advance general dentistry 2001,
Specialty Training / Employment:
2003 August – Present     Consultant- Advanced General Dentist.
King Faisal Specialist Hospital and Research Center - Jeddah
November 2007- Present    Residency Program Director. KFSH&RC, Jeddah
2004- Present                     Member of the organization committee (CME) for the dental conferences held in KFSH&RC under our department
September 2002 - July 2003       Consultant- Advanced General Dentist.
                                                       King Faisal Specialist Hospital and Research Center – Jeddah
March 2002 – September 2002   Associate Consultant – General Dentist.
King Khalid National Guard Hospital, Jeddah Saudi Arabia
July 2001 – March 2002                         Associate Professor, University of Saskatchewan, Canada
September 2000 – July 2001         Assistant Professor
Joined the Department of Community and Clinical Dentistry. The Department of Dentistry, University of Saskatchewan, Canada
December 1993 – April 1996         General Practitioner Riyadh Medical Complex, Riyadh Saudi Arabia

Postgraduate Training
October 1998 – June 1999
Postgraduate Training in Hospital Dentistry, Montreal General Hospital, McGill University, Montreal, Quebec
July 1996 – June 1997
Residency In Advanced Education in General Dentistry, College of Dentistry, Ohio State University